-
Tenax Therapeutics (TENX) Misses Q4 EPS by 38c
-
Tenax Therapeutics maintains LEVEL study enrollment target after review
-
Tenax Therapeutics (TENX) PT Raised to $25 at Guggenheim
-
Tenax Therapeutics (TENX) Misses Q3 EPS by 40c
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Tenax Therapeutics receives European patent intention for levosimendan
-
Piper Sandler Starts Tenax Therapeutics (TENX) at Overweight
-
Tenax Therapeutics (TENX) PT Lowered to $14 at Guggenheim
-
Tenax Therapeutics (TENX) Misses Q2 EPS by 27c
-
Tenax Therapeutics (TENX) Misses Q1 EPS by 28c
-
Tenax Therapeutics (TENX) Misses Q4 EPS by 18c
-
Tenax Therapeutics (TENX) PT Raised to $20 at Leerink Partners
-
Tenax Therapeutics (TENX) announces private placement of $25 million
-
Tenax Therapeutics (TENX) Expands Phase 3 LEVEL Program
-
This stock offers 'tremendous optionality in 2H25': analyst
-
Tenax Therapeutics (TENX) Appoints Gillian Andor Vice President, Clinical Operations
-
Tenax Therapeutics (TENX) Misses Q3 EPS by 19c
-
Leerink Partners Starts Tenax Therapeutics (TENX) at Outperform
-
Tenax Therapeutics (TENX) Misses Q2 EPS by 183c
-
Tenax Therapeutics (TENX) Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
-
Tenax Therapeutics (TENX) Announces $100M Private Placement

